Fulcrum Therapeutics, Inc.

NasdaqGM:FULC Voorraadrapport

Marktkapitalisatie: US$200.3m

Fulcrum Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Fulcrum Therapeutics zullen naar verwachting dalen met respectievelijk 80% en 21.5% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 19.3% per jaar.

Belangrijke informatie

-21.5%

Groei van de winst

-19.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei23.6%
Inkomstengroei-80.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt04 Oct 2024

Recente toekomstige groei-updates

Recent updates

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Sep 12

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12
Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11
News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Winst- en omzetgroeiprognoses

NasdaqGM:FULC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026N/A-55-50-575
12/31/2025N/A-62-46-506
12/31/202480-14-12-57
6/30/202482-20-13-12N/A
3/31/20243-99-92-92N/A
12/31/20233-97-91-91N/A
9/30/20233-99-88-88N/A
6/30/20233-98-93-92N/A
3/31/20234-109-101-99N/A
12/31/20226-110-99-97N/A
9/30/202211-107-102-99N/A
6/30/202214-104-96-94N/A
3/31/202217-90-86-84N/A
12/31/202119-81-80-78N/A
9/30/202118-75-78-76N/A
6/30/202115-73-60-58N/A
3/31/202113-69-56-55N/A
12/31/20209-71-55-54N/A
9/30/20205-69-39-38N/A
6/30/20203-68-48-47N/A
3/31/20201-68-46-45N/A
12/31/2019N/A-90-40-39N/A
9/30/2019N/A-85-46-41N/A
6/30/2019N/A-79-38-32N/A
3/31/2019N/A-71-34-26N/A
12/31/2018N/A-39-32-23N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat FULC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van FULC zal naar verwachting de komende 3 jaar dalen ( -80% per jaar).

Hoge groei-inkomsten: De omzet van FULC zal naar verwachting de komende 3 jaar dalen ( -80% per jaar).


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van FULC naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven